Compare

Coloplast A/S/€COLOB

1D1W1M3M6MYTD1Y5YMAX

About Coloplast A/S

Coloplast A/S is a Danish multinational company that specializes in the development and manufacture of medical devices and services. The company's core business operates within the healthcare sector, offering products and services that focus on ostomy care, urology, continence care, and wound and skin care. Founded in 1957 and headquartered in Humlebæk, Denmark, Coloplast has established a strong presence in numerous countries, serving healthcare professionals and patients around the globe. Its strategic positioning is supported by a commitment to innovation and close collaboration with healthcare professionals to ensure the efficacy and safety of its offerings. Coloplast's competitive strengths derive from its comprehensive product portfolio and strong expertise in chronic care solutions.
Ticker
€COLOB
Sector
Health
Primary listing
XGAT
Employees
17,213
Headquarters
Humlebæk, Denmark
Website
www.coloplast.com

Coloplast A/S Metrics

BasicAdvanced
€14B
38.61
€1.64
0.55
€3.08
4.86%

What the Analysts think about Coloplast A/S

Analyst ratings (Buy, Hold, Sell) for Coloplast A/S stock.
Analyst projections of the future price of Coloplast A/S stock.

Bulls say / Bears say

Continence Care grew 8% and Interventional Urology 7% in the latest quarter, with Luja and US men’s health among the drivers. That breadth suggests Coloplast’s core franchises are still gaining demand despite weakness elsewhere. (Coloplast)
The US accounts for only about a quarter of sales, leaving room to grow in Coloplast’s largest market; recent US chronic-care growth was high single-digit to double-digit. Management is sharpening its US focus, which could help it capture more of that opportunity. (Investing.com, Investing.com)
Cash generation improved: the nine-month free-cash-flow-to-sales ratio reached 20%, compared with 16% a year earlier. Stronger cash flow gives Coloplast more room to fund investment while navigating current setbacks. (Coloplast)
Kerecis remains a serious problem after US Medicare payment changes hit outpatient demand; Coloplast recorded a DKK 3 billion impairment, and the business still faces a difficult recovery. The reimbursement shock has undermined the growth case for a major acquisition. (Reuters)
Profitability is weakening: the latest quarterly EBIT margin fell to 26% from 28% a year earlier. Coloplast attributed the pressure in part to currency effects and Kerecis, while factory ramp-up costs also weighed on margins. (Coloplast, Investing.com)
Near-term growth faces execution risks: a new China channel strategy caused inventory reductions that weighed on sales, while the Intibia launch has been pushed back to 2027/28. Both make it harder to rely on those markets and products to accelerate growth soon. (Investing.com, Inderes)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.

Coloplast A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Coloplast A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Coloplast A/S

AllEURUSDGBP
Funds
Fund name
Fund size
€COLOB weighting
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.08%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.08%
Vanguard FTSE Developed Europe ex UK$VERE
€1.4B0.08%
Vanguard FTSE Developed Europe ex UK£VERX
€3.3B0.08%
Vanguard FTSE Developed Europe ex UK€VERX
€3.3B0.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.